Why Are Investors Talking About These Penny Stocks?
Penny stocks are some of the most interesting investments that one can make. On one hand, the lower prices and high volatility of these cheap stocks mean that there is a lot of potential to be had. On the other hand, those same factors mean that investors can lose a lot, quite quickly. With penny stocks however, the opportunity to find a winner is abound. Because there is such a wide range of penny stocks to watch, investors must do their own research to find out which company suits them best.
There are two strategies to utilize when it comes to investing in penny stocks. The first is the swing or day trading method. This method simply means that investors are in positions for a short period of time from a few minutes to a few weeks. In addition, trading is based on the idea that a given stock will shoot up or down substantially in a shorter time frame. This is best for those who are more risk inclined.
Read More
- Are These The Best Penny Stocks To Watch At The Start of October 2020?
- 3 Penny Stocks To Watch As Gold Prices Rally In October 2020
The second method is the long term investing method. These investors usually hold their positions due to a belief that a company has a solid long term future. Both of these methods have value and both can be winning strategies. But, investors should make sure to know what kind of risk they want to have in their portfolios. Once one has figured that out, it all comes down to research and investigation into a given penny stock. With that in mind, let’s take a look at four penny stocks to watch right now.
Penny Stocks to Watch: GT Biopharma Inc.
GT Biopharma Inc. (GTBP Stock Report) is a clinical-stage producer of immuno-oncology based treatment. The company has several treatments in its pipeline that utilize its advanced TriKE technology. As a small-cap penny stock, the company has a lot of room to research and develop that some larger companies may not have. In addition, the company has been working heavily with the Masonic Cancer Center at the prestigious University of Minnesota.
This cancer center is one of the top institutes in the country and has been a very useful resource to GT Biopharma. Currently, GT is in its Phase I/II clinical trials at the University for its TriKE platform; specifically it GTB-3550 treatment for acute myeloid leukemia (AML). Dr. Jeffery Miller, the consulting Chief Medical Officer at GT Biopharma stated that the company is working on this “designer cancer treatment” that could become a game-changer for immune treatments.
The TriKE platform leverages a protein that binds to a tumor cell and uses the tumor itself to fight off the cancerous cells. This treatment is very different from others and presents a potentially new horizon in the fight against cancer & other immune diseases. In addition, the TriKE methodology is being studied for its effectiveness in several different types of cancer beyond leukemia. This includes ovarian, breast, prostate, and lung cancer. For both GT Biopharma and those who are fighting cancer, the hopes are that this drug can be a major breakthrough.
GT Biopharma has just completed the treatment of the first patient enrolled at Dose Level 3 in its GTB-3550 TriKE™ Phase I/II clinical trial. In short, the findings have already shown promise. Since the start of 2020, GTBP stock is up 75%. Click For More Information On GT Biopharma Inc.
Penny Stocks to Watch: Opko Health Inc.
Opko Health Inc. (OPK Stock Report) is a producer of several pharmaceuticals as well as diagnostic tests. The company is by no means a small-cap penny stock as it has a market cap north of $2 billion. In its most recent first quarter, the company posted a consolidated revenue amount of roughly $211 million.
At the end of the second quarter, the company reported around $34 million in cash and cash equivalents for this division alone. What’s interesting is that the company posted a revenue surge of roughly 33% for this quarter alone. This is due to the company’s role in fighting the COVID pandemic. The company is a large producer of COVID-19 tests that are currently in use by around 35,000 people per day.
In total, the company has tested more than 700,000 people. In the current state of the market, companies that have a role in COVID are usually more volatile than others. But, we have seen this volatility be mostly positive in the past six months. What’s more is that the company is testing its Rayaldee product as a treatment for mild-to-moderate COVID-19 in a Phase 2, randomized, double-blind, placebo-controlled study. Rayaldee is a vitamin D-based drug that has been approved by the Food and Drug Administration as a treatment for certain forms of kidney disease.
[Read More] 4 Penny Stocks To Buy According To Analysts; 1 With A 189% Target
The trial’s 160 participants will primarily include people with stage 3 or 4 chronic kidney disease. Thursday saw OPK stock continue extending its 5-day rally to highs of $3.95 during aftermarket trading. Year-to-date Opko shares are up over 160%. Can this trend continue heading into October? Click For More Information On Opko Health Inc.
Penny Stocks to Watch: Evogene Ltd.
Evogene Ltd. (EVGN Stock Report) is a computational biology company working on the development and discovery of new compounds for use in everything from health to agriculture and more. The company is working on a variety of therapeutics that can be used across the board to treat different disorders as well.
One of the components that makes Evogene a penny stock to watch is that it has a very broad market. The company works in the U.S., Israel, Brazil, and other countries. It also has contracts with Bayer and other big-name pharmaceutical companies.
Throughout September, Evogene stock has performed quite well. A lot of this has to do with a $10 million offering that it completed with ARK Investment Management and Alpha Capital. These funds will go directly into the company’s research pipeline to help produce new drugs utilizing computational biology.
In addition, the company showed very solid clinical results in its latest immune-oncology program. Specifically, the company announced positive pre-clinical in-vivo results in its immuno-oncology program for a follow-on combination of bacterial strains. In these studies, its subsidiary, Biomica tested BMC128, which consists of four live bacterial strains derived from Biomica’s drug candidates BMC121 and BMC127. Treatment with BMC128, both prior to and in combination with ICI, “significantly improved anti-tumor activity” in mice.
Year-to-date EVGN stock is up over 145%. For this reason, it could be one of the penny stock to watch in October. Click For More Information On Evogene Ltd.
Penny Stocks to Watch: CTI BioPharma Corp.
CTI BioPharma Corp. (CTIC Stock Report) is a biopharmaceutical company working on the production and development of several treatments for blood-related cancer. These treatments have helped to push the cutting edge of medicine with these specific illnesses. The company has stated that blood cancers have a distinct need that has not been met by popular biopharmaceutical companies as of yet. In addition, the company has been using its drug pacritinib, to potentially treat different aspects of COVID-19. Based out of Seattle, the company has a unique position in the U.S. pharmaceutical market.
[Read More] 5 Penny Stocks On Robinhood, TD, & Webull To Watch In October 2020
In addition, its treatments have seen a large amount of success in the past few years. Recently, the company announced that it has reached an agreement to accelerate its pacrinitib treatment for myelofibrosis. The company stated, “since the completion of the PAC203 Phase 2 dose-ranging trial, we have been working collaboratively with the FDA to identify an expeditious approval pathway for pacrinitib in myelofibrosis patients.”
Because it has such an advantageous position in the biotech industry, CTI BioPharma has remained on a strong uptrend heading into October. For this reason, it continues to be viewed as one of the biotech penny stocks to watch right now. Due to the huge move CTIC stock has made, however, keep in mind that there’s now a very large gap up in the stock. The big question is, can CTI maintain new support at these higher levels? Year-to-date, CTIC stock is up 53%. Click For More Information On CTI BioPharma Corp.
Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP), GT Biopharma is required to pay $200,000 per month for 4 months of services, $400,000 of which has already been paid for 2 months of services (first and last month) for a period from September 22, 2020 to January 22, 2021. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP).
